GlobalResearch and clinical trials
Light-sensitive molecule tested in the eye for the first time in 6 people with advanced retinitis pigmentosa
In Australia, a drug was injected into 12 eyes of 6 people with advanced RP.
Eye and hearing diseases
An inherited disease that affects the retina, the light-sensing layer at the back of the eye. Night vision is the first to get worse. The field of vision narrows over the years.
Not part of the panel of Türkiye's National Newborn Screening Programme (heel-prick test). Source
This page is translated from the Turkish original.
This disease is followed through the “Eye and hearing diseases” group.
The retina is a thin layer at the back of the eye that senses light. It contains light cells called rods and cones. In RP, these cells slowly break down. First the rods, which allow vision in the dark, are affected, then the cones. Sometimes RP is part of a syndrome together with other problems such as hearing loss.
Symptoms usually begin in childhood or young adulthood. How fast vision is lost varies from person to person.
The eye doctor widens the pupil with drops and looks at the retina. A visual field test measures side vision. A test called ERG measures how the retina responds to light. OCT takes a detailed picture of the retina. A genetic test helps to find out the type of RP.
There is not yet a treatment that stops most types of RP. For people with low vision, aids and vision training help them make the best use of their remaining sight. Some vitamin supplements may slow the loss. But too much can be harmful, so it is necessary to ask the doctor. Regular eye checks catch additional problems such as cataract early. Sunglasses protect the eyes from light. There is an approved gene therapy for a small group with two changes in the RPE65 gene. Research on gene, cell and drug therapies is ongoing. The doctor who follows the disease decides which treatment is suitable.
RP can be inherited in different ways. In the dominant type, the chance of passing it from an affected parent to a child is 1 in 2 in each pregnancy. In the recessive type, the chance of an affected child for a carrier couple in each pregnancy is 1 in 4. Recessive types may be more likely when parents are related by blood. In the X-linked type, mostly males are affected. Genetic counselling explains the type and the risk in the family.
Source: MedlinePlus Genetics: Retinitis pigmentosa · National Eye Institute (NIH): Retinitis Pigmentosa · NORD: Retinitis Pigmentosa
These facts are taken from Orphanet and MedlinePlus records (last checked: October 7, 2026). Frequency values are approximate ranges.
Non-profit patient and family organizations in Türkiye working on this disease or disease group. Links are for information; Doktorclub is not affiliated with these organizations and does not endorse them.
We could not find a patient association specific to this disease.
For all rare diseases: Nadir Hastalıklar Federasyonu
Doktorclub does not diagnose, recommend treatments or refer you to hospitals or doctors. These pages are meant to help you talk with your doctor.
GlobalResearch and clinical trials
In Australia, a drug was injected into 12 eyes of 6 people with advanced RP.
TürkiyeResearch and clinical trials
In Erzincan, face-to-face interviews were held with adults with retinitis pigmentosa.
A clinical trial is a regulated study that tests whether a new treatment is safe and whether it works, in patients who volunteer. Most trials look for a certain age, genetic change and health condition. Taking part is voluntary.
Questions you can ask your doctor
ClinicalTrials.gov lists 67 active interventional studies for this disease. 24 are recruiting now; none has a site in Türkiye. Last checked: October 7, 2026.
Selected records (studies with a site in Türkiye first):
Early stage: safety and dose are being tested · Phase 1 · investigational (experimental)RecruitingNCT07774975
Middle stage: the effect is being tested in a small group · Phase 1 / Phase 2 · investigational (experimental)RecruitingNCT07408232
Early stage: safety and dose are being tested · Phase 1 · investigational (experimental)RecruitingNCT06319872
Middle stage: the effect is being tested in a small group · Phase 1 / Phase 2 · investigational (experimental)RecruitingNCT07807111
Middle stage: the effect is being tested in a small group · Phase 1 / Phase 2 · investigational (experimental)RecruitingNCT06789445
See all studies on ClinicalTrials.gov · Joining clinical trials
TürkiyeSGK and reimbursement
A drug used for a rare disease affecting the optic nerve has been added to reimbursement coverage.
USAResearch and clinical trials
A two-year, placebo-controlled study was carried out at 7 centers in the USA.
TürkiyeResearch and clinical trials
Gazi University studied the eyes of 27 children.
These codes identify the disease in international classifications and databases. They can help when you talk with your doctor or look for reliable sources.
Orphanet code: ORPHA:791
No separate ICD-11 code; WHO classifies this disease under: 9B70
Codes checked against WHO ICD-11 and Orphanet on October 7, 2026.
This page provides general information and does not replace diagnosis or treatment. Talk to your doctor about symptoms, diagnosis and treatment.